Drug Type Small molecule drug |
Synonyms MMKI + [3] |
Target |
Mechanism FGFRs antagonists(Fibroblast growth factor receptors antagonists), VEGFR2 antagonists(Vascular endothelial growth factor receptor 2 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC27H26F5N7O3 |
InChIKeyGZPJCJKUZPUFAL-UHFFFAOYSA-N |
CAS Registry939805-30-8 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 2 | CN | 29 May 2018 | |
Neoplasms | Phase 2 | US | 01 Jan 2010 | |
Bile Duct Neoplasms | Phase 1 | CN | 09 Jul 2018 | |
Bladder Cancer | Phase 1 | CN | 09 Jul 2018 | |
Breast Cancer | Phase 1 | CN | 09 Jul 2018 | |
Stomach Cancer | Phase 1 | CN | 09 Jul 2018 | |
Neoplasms | Phase 1 | US | 01 Jan 2010 |